ASL Pescara General Hospital, Member of Drug Utilization Research Group for Italian Society of Hospital Pharmacist (SIFO), Renato Paolini 47 65124, Pescara, Italy.
Curr Rev Clin Exp Pharmacol. 2021;16(1):109-116. doi: 10.2174/1574884715666200309121932.
Persistence and adherence to treatment are considered efficacy outcomes in psychiatric disorders. One of the best ways to improve these values in patients with psychiatric disorders is to prefer Long-Acting Injectable (LAI) drugs to oral AP.
The objective of this study is to evaluate adherence, persistence and switching of antipsychotics and compare in real life long-acting with oral formulations.
This pharmacological, observational, retrospective and non-interventional study involved all patients of the ASL of Pescara treated in the front-line with AP in the period between January 2011 and February 2019. Adherence was measured using the ratio between the received daily dose and prescribed daily dose. Persistence to treatment with antipsychotics was calculated as the daily difference between the beginning and end of treatment.
We examined 840 patients treated with aripiprazole, 130 patients treated with paliperidone and 925 patients treated with risperidone. Adherence was significantly better in long-acting formulations with values of 0.89 (aripiprazole) and 0.82 (paliperidone and risperidone) than in oral formulations with values of 0.78, 0.70 and 0.58, respectively (p> 0.999, p= 0.0091, p=< 0.0001). Threeyear persistence curves relating to three study drugs did not show a statistically significant difference (p = 0.3314). Persistence curves based on formulation have not shown a statistically significant difference (p= 0, 4658, p=0, 4794, p=0, 2199 for ariprazolo, paliperidone and risperidone, respectively). 7% of patients were treated with aripiprazole, 12% of patients were treated with risperidone and 28% of patients were treated with paliperidone switched therapy.
In all the drugs of present study, adherence values were better in LAI than in OA, whereas no statistically significant difference was found in persistence values.
在精神疾病中，坚持和治疗依从性被认为是疗效的结果。提高精神疾病患者这些数值的最佳方法之一是优先使用长效注射（LAI）药物而不是口服药物。
本研究旨在评估抗精神病药物的依从性、持续性和转换，并比较现实生活中长效和口服制剂。
这是一项药理学、观察性、回顾性和非干预性研究，涉及 2011 年 1 月至 2019 年 2 月期间在佩斯卡拉 ASL 接受一线治疗的所有接受 AP 治疗的患者。使用接受的每日剂量与规定的每日剂量之间的比值来衡量依从性。抗精神病药物治疗的持续性计算为治疗开始和结束之间的每日差异。
我们检查了 840 例接受阿立哌唑治疗的患者、130 例接受帕利哌酮治疗的患者和 925 例接受利培酮治疗的患者。长效制剂的依从性明显更好，数值为 0.89（阿立哌唑）和 0.82（帕利哌酮和利培酮），而口服制剂的数值分别为 0.78、0.70 和 0.58（p>0.999，p=0.0091，p<0.0001）。三种研究药物的三年持续性曲线没有显示出统计学上的显著差异（p=0.3314）。基于制剂的持续性曲线没有显示出统计学上的显著差异（p=0、4658、p=0、4794、p=0、2199 分别用于阿立哌唑、帕利哌酮和利培酮）。7%的患者接受阿立哌唑治疗，12%的患者接受利培酮治疗，28%的患者接受帕利哌酮转换治疗。
在本研究中的所有药物中，LAI 的依从性值优于 OA，而持续性值没有统计学上的显著差异。
